Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.
作者信息
Kuenzig M Ellen, Widdifield Jessica, Bernatsky Sasha, Kaplan Gilaad G, Benchimol Eric I
机构信息
SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada; Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto, ON, Canada; ICES, Toronto, ON, Canada.
出版信息
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):288-289. doi: 10.1016/S2468-1253(22)00054-1. Epub 2022 Feb 23.
Abstract
摘要
相似文献
1
Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.加拿大安大略省炎症性肠病患者中 SARS-CoV-2 疫苗第三剂的接种情况。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):288-289. doi: 10.1016/S2468-1253(22)00054-1. Epub 2022 Feb 23.
2
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.炎症性肠病患者接种第三剂SARS-CoV-2疫苗的影响因素。
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):507. doi: 10.1016/S2468-1253(22)00120-0. Epub 2022 Apr 6.
3
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].[成人炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明]
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
4
SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire.炎症性肠病患者对SARS-CoV-2疫苗接种的恐惧与期望
Inflamm Bowel Dis. 2021 Oct 20;27(11):1858-1861. doi: 10.1093/ibd/izab150.
5
The impact of SARS-CoV-2 variants on IBD management.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体对炎症性肠病管理的影响。
Lancet Gastroenterol Hepatol. 2021 May;6(5):343-344. doi: 10.1016/S2468-1253(21)00075-3. Epub 2021 Mar 10.
6
Fracturing political commitment to implement vaccine mandates.破坏实施疫苗强制令的政治承诺。
CMAJ. 2021 Nov 29;193(47):E1819. doi: 10.1503/cmaj.1095975.
7
Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients.儿童炎症性肠病患者感染或接种SARS-CoV-2后的血清转化
Inflamm Bowel Dis. 2021 Oct 20;27(11):1862-1864. doi: 10.1093/ibd/izab194.
8
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
9
Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey.意大利南部一组炎症性肠病患者对严重急性呼吸综合征冠状病毒2疫苗的接受情况：一项横断面调查。
Inflamm Bowel Dis. 2021 Oct 20;27(11):e134-e135. doi: 10.1093/ibd/izab133.
10
Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.炎症性肠病患者对前四剂严重急性呼吸综合征冠状病毒2疫苗的血清学反应。
Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1077-1079. doi: 10.1016/S2468-1253(22)00340-5. Epub 2022 Oct 26.
引用本文的文献
1
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
2
The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.2023年炎症性肠病对加拿大的影响：COVID-19与炎症性肠病
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S76-S82. doi: 10.1093/jcag/gwad019. eCollection 2023 Sep.
3
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.英夫利昔单抗和维多珠单抗治疗的炎症性肠病患者对COVID-19疫苗加强针的接种意愿：一项横断面研究
Vaccines (Basel). 2022 Jul 22;10(8):1166. doi: 10.3390/vaccines10081166.
4
Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.社论：COVID-19 疫苗在炎症性肠病患者中安全有效——但仍有许多悬而未决的问题。
Aliment Pharmacol Ther. 2022 Jul;56(1):162-163. doi: 10.1111/apt.16935.
5
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
6
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis.2021年3月1日至11月22日在加拿大安大略省对患有免疫介导的炎症性疾病的个体进行的SARS-CoV-2感染疫苗有效性及严重后果的基于人群的分析。
Lancet Rheumatol. 2022 Jun;4(6):e430-e440. doi: 10.1016/S2665-9913(22)00096-0. Epub 2022 Apr 14.
本文引用的文献
1
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.炎症性肠病（IBD）免疫抑制患者 COVID-19 疫苗诱导的抗体反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352. doi: 10.1016/S2468-1253(22)00005-X. Epub 2022 Feb 4.
2
Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada.验证国际算法在加拿大安大略省健康管理数据中识别成人炎症性肠病的有效性。
J Clin Epidemiol. 2014 Aug;67(8):887-96. doi: 10.1016/j.jclinepi.2014.02.019. Epub 2014 Apr 26.
3
Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data.加拿大安大略省儿童炎症性肠病发病率上升：来自卫生行政数据的证据。
Gut. 2009 Nov;58(11):1490-7. doi: 10.1136/gut.2009.188383. Epub 2009 Aug 2.
Zotero 插件